Amifostine, originally developed to protect against chemotherapy and radiation toxicity, shows potential as a treatment for idiopathic pulmonary fibrosis (IPF). This chronic lung disease involves irreversible scarring and mitochondrial dysfunction. In studies, amifostine reduced fibrosis by targeting mitochondrial ROS and restoring energy balance. It activates SIRT1 and AMPK, crucial for maintaining mitochondrial health, highlighting its role in combating oxidative stress and fibrosis progression.
Guo, F., Xu, F., Li, S., Zhang, Y., Lv, D., Zheng, L., Gan, Y., Zhou, M., Zhao, K., Xu, S., Wu, B., Deng, Z. and Fu, P., 2024. Amifostine ameliorates bleomycin-induced murine pulmonary fibrosis via NAD+/SIRT1/AMPK pathway-mediated effects on mitochondrial function and cellular metabolism. European Journal of Medical Research
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For more details consult with your doctor or healthcare professional.
Guo, F., Xu, F., Li, S., Zhang, Y., Lv, D., Zheng, L., Gan, Y., Zhou, M., Zhao, K., Xu, S., Wu, B., Deng, Z. and Fu, P., 2024. Amifostine ameliorates bleomycin-induced murine pulmonary fibrosis via NAD+/SIRT1/AMPK pathway-mediated effects on mitochondrial function and cellular metabolism. European Journal of Medical Research
Guo, F., Xu, F., Li, S., Zhang, Y., Lv, D., Zheng, L., Gan, Y., Zhou, M., Zhao, K., Xu, S., Wu, B., Deng, Z. and Fu, P., 2024. Amifostine ameliorates bleomycin-induced murine pulmonary fibrosis via NAD+/SIRT1/AMPK pathway-mediated effects on mitochondrial function and cellular metabolism. European Journal of Medical Research
Guo, F., Xu, F., Li, S., Zhang, Y., Lv, D., Zheng, L., Gan, Y., Zhou, M., Zhao, K., Xu, S., Wu, B., Deng, Z. and Fu, P., 2024. Amifostine ameliorates bleomycin-induced murine pulmonary fibrosis via NAD+/SIRT1/AMPK pathway-mediated effects on mitochondrial function and cellular metabolism. European Journal of Medical Research